🏛️ Verified NIH Record • Updated 2026-06-09

A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant (NCT07095452)

Phase 2/3, Multicenter, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Subjects With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant

🟢 Recruiting Phase2 / Phase3 💊 Investigational Drug / Biologic Sponsor: AbbVie

🩺 Plain-English Summary (8th-Grade Level)

Multiple myeloma (MM) is a cancer of the blood's plasma cells. The cancer is typically found in the bones and bone marrow (the spongy tissue inside of the bones) and can cause bone pain, fractures, infections, weaker bones, and kidney failure. This is a study to determine the adverse events, change in disease activity, and pharmacokinetics of Etentamig in adult participants with MM. Etentamig is an investigational drug being developed for the treatment of MM. This study is broken into 2 phases; phase 2 with 3 study arms and phase 3 with 2 study arms. Participants in phase 2 will receive 1 of 3 doses of etentamig in combination with daratumumab. Participants in phase 3 will receive etentamig at RP3D in combination with daratumumab, or daratumumab, lenalidomide, and dexamethasone (DRd). Around 660 adult participants with MM will be enrolled at approximately 155 sites worldwide Participants in phase 2 will receive 1 of 3 doses of etentamig as intravenous (IV) infusions, combination with subcutaneous (SC) injections of daratumumab. Participants in phase 3 will receive RP3D doses of etentamig as IV infusions, combination with SC injections of daratumumab, or SC injections of daratumumab, capsules of lenalidomide, and tablet/ IV injections of dexamethasone (DRd). The study duration is approximately 16 years. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and questionnaires.

Who can join: Review the eligibility criteria below.

Location: Mayo Clinic Hospital Scottsdale /ID# 278349 — Scottsdale, Arizona

Age range: 18 Years

🧪 Interventions in This Study

📋 "Do I Qualify?" — 1-Minute Self Screener

Instant Checklist

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (49 Sites)

Showing the first 25 of 49 sites.

  • Mayo Clinic Hospital Scottsdale /ID# 278349 — Scottsdale, Arizona
  • Cedars-Sinai Medical Center /ID# 278238 — Los Angeles, California
  • Colorado Blood Cancer Institute /ID# 279080 — Denver, Colorado
  • Winship Cancer Institute of Emory University /ID# 277667 — Atlanta, Georgia
  • Fort Wayne Medical Oncology And Hematology /ID# 278141 — Fort Wayne, Indiana
  • Minnesota Oncology - Minneapolis Clinic /ID# 278720 — Minneapolis, Minnesota
  • Mayo Clinic Hospital Rochester /ID# 277886 — Rochester, Minnesota
  • Icahn School of Medicine at Mount Sinai /ID# 277844 — New York, New York
  • Memorial Sloan Kettering Cancer Center - New York - York Avenue /ID# 277946 — New York, New York
  • Weill Cornell Medicine Myeloma Center /ID# 278216 — New York, New York
  • University of North Carolina at Chapel Hill /ID# 277708 — Chapel Hill, North Carolina
  • Willamette Valley Cancer Institute and Research Center /ID# 278721 — Eugene, Oregon
  • SCRI Oncology Partners /ID# 278353 — Nashville, Tennessee
  • Texas Oncology - The Woodlands /ID# 278726 — The Woodlands, Texas
  • Texas Oncology - Northeast Texas /ID# 278725 — Tyler, Texas
  • Virginia Cancer Specialists - Fairfax /ID# 278716 — Fairfax, Virginia
  • Blue Ridge Cancer Care - Roanoke /ID# 278722 — Roanoke, Virginia
  • Centre Hospitalier Annecy Genevois /ID# 278406 — Epagny Metz Tessy, Auvergne-Rhône-Alpes
  • Centre Hospitalier De Dunkerque-Hospital Alexandra Lepeve /ID# 278399 — Dunkirk, Hauts-de-France
  • Chu De Lille - Hopital Claude Huriez /ID# 278413 — Lille, Hauts-de-France
  • CHU de Montpellier - Hopital Saint Eloi /ID# 278415 — Montpellier, Herault
  • CHRU Tours - Hopital Bretonneau /ID# 279274 — Tours, Indre-et-Loire
  • CH Bretagne Atlantique /ID# 278422 — Vannes, Morbihan
  • Centre Hospitalier Universitaire de Bordeaux /ID# 278419 — Pessac, New Aquitaine
  • Centre Hospitalier Universitaire de Poitiers /ID# 278398 — Poitiers, New Aquitaine

📞 Contact the Study Coordinator

Phone: (844) 663-3742

Email: abbvieclinicaltrials@abbvie.com

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

  • 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
  • Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
  • Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Multiple Myeloma

Explore by condition: All Multiple Myeloma clinical trials

💡 How to Participate

  1. Check the checklist above to see if you may qualify.
  2. Contact the study coordinator using the phone/email above.
  3. Ask about the visit schedule, what is covered at no cost, and any travel support.
  4. Confirm with your own doctor before making a decision.
🏛️ View Official NIH Record ↗